Sugi Predict

Sugi Predict / Compounds / SCHEMBL26348164

SCHEMBL26348164

SCHEMBL26348164

CCCCc1nc2c(N)nc(O)nc2n1CCCCN

nearest known ligand 0.54

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ TLR7 Q9NYK1 14/20 0.54
▸ TLR8 Q9NR97 7/20 0.54
▸ HSP90AA1 P07900 2/20 0.39
▸ HSP90AB1 P08238 2/20 0.39
▸ DYRK1A Q13627 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29475714 1.00 TLR7 (0.54) TLR7TLR8HSP90AA1HSP90AB1DYRK1A
SCHEMBL30503500 0.80 ADORA2A (0.59) TLR7TLR8HSP90AA1HSP90AB1
SCHEMBL22359153 0.80 ADORA2A (0.59) TLR7TLR8HSP90AA1HSP90AB1
SCHEMBL26348167 0.77 TLR7 (0.44) TLR7TLR8
SCHEMBL6094864 0.74 TLR7 (0.63) TLR7TLR8
SCHEMBL3820084 0.70 TLR7 (0.57) TLR7TLR8
SCHEMBL1615627 0.70 TLR7 (1.00) TLR7TLR8
SCHEMBL3863599 0.69 TLR7 (0.98) TLR7TLR8
SCHEMBL14659348 0.69 TLR7 (0.50) TLR7
SCHEMBL14667664 0.69 ADORA2A (0.38) TLR7TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12569566-B2 Compositions containing, methods and uses of antibody-TLR agonist conjugates AMBRX, INC. (US) 2026-03-10 — — US disclosed
US-20230302150-A1 ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF AMBRX, INC. (US) 2023-09-28 — — US disclosed
US-20230302150-A1 ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF AMBRX, INC. (US) 2023-09-28 — — US disclosed
US-20230302150-A1 ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF AMBRX, INC. (US) 2023-09-28 — — US disclosed
CN-116457023-A antibody-TLR agonist conjugates, methods and uses thereof AMBRX公司 2023-07-18 — — CN disclosed
EP-4199968-A1 ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF Ambrx, Inc. (US) 2023-06-28 — — EP disclosed
US-20220226488-A1 COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES AMBRX, INC. 2022-07-21 — — US disclosed
WO-2022040596-A1 ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF AMBRX, INC. (US) 2022-02-24 — — WO disclosed
CN-113660957-A Compositions, methods, and uses comprising antibody-TLR agonist conjugates AMBRX公司 2021-11-16 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230302150-A1 ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF TLR3, TLR1, TLR9 TLR7 4/4885TLR8 9/4885HSP90AA1 1271/4885
US-20220226488-A1 COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES TLR1, TLR3, TLR2 TLR7 7/4885TLR8 9/4885HSP90AA1 694/4885
US-12569566-B2 Compositions containing, methods and uses of antibody-TLR agonist conjugates TLR3, TLR2, TLR1 TLR7 8/4885TLR8 7/4885HSP90AA1 2594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.